Incannex Healthcare Inc. Overview
Pro stress-test →Incannex Healthcare is a clinical-stage biopharmaceutical company engaged in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company is innovating novel oral treatments, starting with obstructive sleep apnea.
Strategic Profile
Pro stress-test →The company develops IHL-42X (dronabinol and acetazolamide combination in Phase 2/3 trial for obstructive sleep apnea), PSX-001 (synthetic psilocybin for generalized anxiety disorder), and IHL-675A (synthetic cannabidiol and hydroxychloroquine for rheumatoid arthritis and inflammatory conditions). Incannex positions itself as a science-led innovator combining cannabinoid and psychedelic pharmaceutical approaches with multi-indication potential.
Competitive Landscape
Pro stress-test →Incannex competes in the emerging psychedelic medicine and cannabinoid pharmaceutical spaces against specialized biotech firms (Compass Pathways, Atai Life Sciences, Tilray) and larger pharma R&D programs. Its multi-indication approach differs from single-asset psychedelic specialists, while its cannabinoid portfolio mirrors broader cannabis-derived pharmaceutical development trends.
Industry Context
Incannex Healthcare Inc. operates in Clinical-stage Biopharmaceutical / Psychedelic & Cannabinoid Therapeutics.
Key facts
Headquarters: Sydney, Australia · Market cap: $135.03M